Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Catholic Hospital System Ends Joint Venture With Mass. Insurer Over Differences On Abortion
Massachusetts-based Catholic hospital system Caritas Christi Health Care on Friday ended its joint venture with the Missouri-based health insurer Centene after Cardinal Sean O"Malley of the Archdiocese of Boston insisted that the relationship linked Catholic hospitals too closely to abortion providers, the AP/San Francisco Chronicle reports (AP/San Francisco Chronicle, 6/27). Under the joint venture, Caritas and Centene created a new company, CeltiCare, which would have insured thousands of low-income Massachusetts residents under Commonwealth Care, the state"s subsidized health care program. Financially troubled Caritas, which was founded by the Archdiocese of Boston, said it will continue to participate as a provider in Commonwealth Care but will no longer be a co-owner of the insurance venture with Centene. Caritas will provide care to patients covered by Centene, as it does for patients covered by other private insurers, but it will not provide any services that violate Catholic teachings, such as abortions or sterilizations. In terminating the joint venture, the archdiocese hopes to appease criticism that Caritas would have profited from abortion and other services provided at non-Catholic medical centers, the Boston Globe reports. According to the archdiocese, O"Malley sought the withdrawal after weeks of consultation with the church-affiliated think tank National Catholic Bioethics Center, in response to harsh criticism from antiabortion-rights groups for not blocking the agreement. The withdrawal is "a vindication of sorts" for O"Malley"s critics, who have argued that it would be wrong for Caritas to enter an agreement with a health insurer that covers abortion care, according to the Globe. Andrea Miller, the executive director of NARAL Pro-Choice Massachusetts, said that Caritas" involvement in the joint venture had raised concern from NARAL because of the Catholic Church"s opposition to abortion rights. She said that although Caritas has withdrawn from the venture, "[t]he question remains: Will the involvement of Caritas Christi health providers negatively affect women"s ability to get timely access to reproductive services, including birth control?" Miller added that NARAL hopes that state regulators "will continue due diligence to ensure that referrals and services are provided in a manner that does not delay access to reproductive health services" (Paulson/Lazar, Boston Globe, 6/27).

Calypso Medical Study Shows Potential For Improving Radiotherapy Treatment Accuracy Of Deadly Pancreatic Tumors
Calypso Medical Technologies, Inc., announced the publication of data from a clinician sponsored investigational study conducted at the University of Pennsylvania, demonstrating the utility of the Calypso® System in tracking tumor movement in the pancreas. The data will be presented at the 51st Annual Meeting of the American Association of Physicists in Medicine (AAPM), July 26-30, at the Anaheim Convention Center. "In areas of the body, such as the pancreas, that are susceptible to respiratory motion it can prove difficult to handle the spectrum of motion that can arise," said James Metz, M.D., Clinical Director, Department of Radiation Oncology, The University of Pennsylvania Health System.
News of the day
Compugen Announces Positive Therapeutic Effects Of Novel Peptide In Animal Model Of Inflammatory Bowel Disease
Compugen Ltd. (NASDAQ:CGEN) announced that CGEN-25007, a novel peptide antagonist of gp96 with potent anti-inflammatory activity, has shown positive therapeutic effects in an animal model of inflammatory bowel disease (IBD), a commonly used term covering ulcerative colitis and Crohn"s disease.
Public Health

Promising Antimicrobial Attacks Virus, Stimulates Immune System

A promising antimicrobial agent already known to kill bacteria can also kill viruses and stimulate the innate immune system, according to researchers at National Jewish Health. In a paper appearing online June 4 in the Journal of Investigative Dermatology, Michael Howell, PhD, Assistant Professor of Pediatrics, and his colleagues demonstrated that the synthetic compound CSA-13 can kill vaccinia virus in cell cultures and in mice. Additionally, they showed that CSA-13 stimulates cells to produce their own antimicrobial proteins. "This compound is demonstrating broad effectiveness," said Dr. Howell. "While our experiments were designed to test its ability to attack the vaccinia virus, its immune-stimulating ability was a surprising observation." CSA-13 is one of a class of compounds known as ceragenins, which were developed by Brigham Young University Professor Paul Savage to mimic antimicrobial proteins that occur naturally in the body. The ceragenins are smaller than antimicrobial proteins, and are not as vulnerable to degradation in the body. They have previously been shown to be effective against a variety of bacterial species. Dr. Howell and his colleagues wanted to learn if CSA-13 could fight vaccinia virus infections. Vaccinia virus is closely related to the organism that causes smallpox and is used in smallpox vaccines. However, millions of people in the United States who have had eczema are susceptible to a serious and potentially fatal complication of the vaccination, known as eczema vaccinatum, which occurs when the vaccinia virus infects the skin. Dr. Howell is part of a team, led by Professor of Allergy and Clinical Immunology Donald Leung, MD, PhD, that is seeking protection against this complication so that eczema patients could receive the vaccination in case of a bioterrorist attack with smallpox. CSA-13 demonstrated effectiveness against vaccinia in three different tests. When CSA-13 and vaccinia virus were directly incubated together, the CSA-13 killed more than 96% of the virus at a 25 micromolar concentration. When CSA-13 was added to cells infected with vaccinia, it both reduced vaccinia virus gene expression and allowed more of the infected cells to survive. Finally, the researchers infected immune-compromised mice with vaccinia virus, then applied CSA-13 onto their skin. The CSA-13 reduced the number of skin lesions caused by vaccinia virus. "These experiments definitively showed for the first time CSA-13 can effectively fight vaccinia virus infections," said senior author Dr. Leung. Within their experiments, the researchers found that, in addition to directly killing the virus, CSA-13 also stimulated cells to produce their own antimicrobial proteins, LL-37 and HBD-3. Dr. Howell and colleagues have previously shown that these antimicrobial proteins also exhibit antiviral activity against vaccinia virus. "We knew from our plaque assays, that CSA-13 was directly killing the virus," said Dr. Howell. "But these experiments show that it also stimulates cells to produce their own antimicrobial proteins, which contribute to its disease-fighting capabilities. Our next step is to learn how CSA-13 stimulates cells" own innate immune defenses." This research was funded entirely by the National Institutes of Health. Adam Dormuth National Jewish Medical and Research Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009